Echo touts positive results for transdermal system; pSivida gets patent for micro needle;

 @DamianFierce: One U.K. company is developing a chocolate-based drug delivery platform, and NIH has taken notice. Report | Follow @DamianFierce

> During the weekend's American Diabetes Association gathering, Echo Therapeutics ($ECTE) unveiled trial data of its Symphony tCGM glucose monitor--which uses the company's skin-permeation platform--demonstrating the device's accuracy. More

> Biodel ($BIOD) has licensed Aegis Therapeutics' transmucosal absorption tech Intravail to develop glucagon treatments for diabetics. News

> pSivida, maker of drug-emitting back-of-the-eye implants, secured a patent for a new inserter the company says will allow doctors to get its devices into patients with far less force. Story

> Drug delivery CRO Particle Sciences has expanded its offerings to include polymer-based films that can deliver liquid-formulation drugs. Release

Suggested Articles

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.

Alexion's 100 mg/ml Ultomiris formulation is expected to slash infusion times by about 60% and bodes well for a planned subcutaneous version, too.

Kindeva, which produces inhalers, transdermal patches and other medical devices, is expanding operations in the St. Paul, Minnesota, area.